oral irreversible FGFR1-4 inhibitor

in Ph. I-III trials for FGFR+ advanced tumors

from structure-based design

Cancer Res., Sep. 24, 2020

Taiho Pharmaceutical, Tokyo, JP

Structure of futibatinib (Tas-120)

TAS-120 (futibatinib) is an orally available, irreversible FGFR1-4 inhibitor with a unique binding mode, targeting a unique cysteine in the P-loop of the FGFRs, rather than the Cys in the…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: